Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of WVT078 With or Without WHG626 in Relapsed/Refractory Multiple Myeloma
jRCT2080225301Phase 1Completed
- Sponsor
- Novartis
- Start
- Aug 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of WVT078 in multiple myeloma (MM) (2 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability of WVT078 alone and in combination with WHG626. Started Aug 2020; status: completed.
02
Drugs
WVT078
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080225301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225301.